Eton Historical Income Statement
| ETON Stock | USD 11.23 0.48 4.47% |
Historical analysis of Eton Pharmaceuticals income statement accounts such as Selling General Administrative of 12.9 M or Total Revenue of 33.2 M can show how well Eton Pharmaceuticals performed in making a profits. Evaluating Eton Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eton Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Eton Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eton Pharmaceuticals is a good buy for the upcoming year.
Eton |
About Eton Income Statement Analysis
Eton Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eton Pharmaceuticals shareholders. The income statement also shows Eton investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Eton Pharmaceuticals Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Eton Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eton Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.At this time, Eton Pharmaceuticals' Income Tax Expense is very stable compared to the past year. As of the 25th of November 2024, Net Interest Income is likely to grow to about 528.1 K, while Selling General Administrative is likely to drop about 12.9 M.
| 2023 | 2024 (projected) | Depreciation And Amortization | 901K | 783.6K | Interest Income | 323.2K | 244.8K |
Eton Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Eton Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eton Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 281K | 889K | 1.0M | 955K | 503K | 596.8K | |
| Selling General Administrative | 7.6M | 12.8M | 14.5M | 18.6M | 18.9M | 12.9M | |
| Total Revenue | 959K | 39K | 21.8M | 21.3M | 31.6M | 33.2M | |
| Gross Profit | 506K | (247K) | 19.2M | 14.3M | 21.1M | 22.1M | |
| Other Operating Expenses | 19.6M | 27.2M | 23.3M | 29.5M | 32.8M | 22.4M | |
| Operating Income | (18.6M) | (27.1M) | (1.5M) | (8.3M) | (1.2M) | (1.3M) | |
| Net Income From Continuing Ops | (18.3M) | (28.0M) | (2.0M) | (9.0M) | (936K) | (982.8K) | |
| Ebit | (18.6M) | (27.1M) | (1.6M) | (8.3M) | (1.2M) | (1.3M) | |
| Research Development | 11.6M | 14.1M | 6.2M | 4.0M | 3.3M | 5.8M | |
| Cost Of Revenue | 453K | 286K | 2.6M | 6.9M | 10.6M | 11.1M | |
| Total Operating Expenses | 19.1M | 26.9M | 20.7M | 22.6M | 22.3M | 20.8M | |
| Income Before Tax | (18.3M) | (28.0M) | (2.0M) | (9.0M) | (689K) | (723.5K) | |
| Total Other Income Expense Net | 281K | (859K) | (460K) | (761K) | 503K | 528.2K | |
| Net Income Applicable To Common Shares | (18.3M) | (28.0M) | (2.0M) | (9.0M) | (10.4M) | (10.9M) | |
| Net Income | (18.0M) | (28.8M) | (3.0M) | (9.8M) | (936K) | (982.8K) | |
| Income Tax Expense | (281K) | 859K | 1.0M | 761K | 247K | 259.4K | |
| Net Interest Income | 281K | (859K) | (1.0M) | (761K) | 503K | 528.2K | |
| Ebitda | (18.2M) | (26.5M) | (1.1M) | (6.5M) | (291K) | (305.6K) | |
| Reconciled Depreciation | 447K | 651K | 462K | 1.8M | 901K | 788.0K |
Pair Trading with Eton Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eton Stock
| 0.94 | GMAB | Genmab AS | PairCorr |
| 0.93 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.87 | LEGN | Legend Biotech Corp | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eton Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Earnings Share (0.26) | Revenue Per Share 1.219 | Quarterly Revenue Growth (0.24) | Return On Assets (0.12) |
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.